GlassScriptPhysician profile
Edward A Wagner
NPI 1487799474
$2,256.28
in general payments reported to CMS, 2019-2025
38 companies · $85.73 in 2025
The $85.73 reported for 2025 was less than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $755 · 2020: $621 · 2021: $400 · 2022: $328 · 2023: $14.77 · 2024: $52.20 · 2025: $85.73.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $105 · Education: $47.49.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $105.21 |
| Education | $47.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $296.47 | 2019-2023 | Abilify |
| Astellas Pharma US INC | $177.88 | 2019-2021 | |
| Pfizer INC. | $172.00 | 2019-2022 | |
| Janssen Scientific Affairs, LLC | $140.53 | 2022 | |
| Celgene Corporation | $132.99 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $124.86 | 2019-2022 | |
| Genzyme Corporation | $87.79 | 2019-2021 | |
| Janssen Biotech, INC. | $86.48 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $85.41 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $67.32 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $66.85 | 2019-2020 | |
| Glaxosmithkline, LLC. | $65.71 | 2021-2025 | Jemperli |
| Lilly USA, LLC | $53.45 | 2020-2022 | |
| Mylan Institutional INC. | $52.61 | 2019-2020 | |
| Tempus Ai, INC | $52.20 | 2024 |
Show all 38 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $47.46 | 2019-2020 | |
| Pharmacyclics LLC, An Abbvie Company | $39.80 | 2019-2020 | |
| Alexion Pharmaceuticals, INC. | $37.70 | 2019-2021 | |
| Abbvie INC. | $36.49 | 2019-2025 | |
| Genentech USA, INC. | $33.34 | 2019-2020 | |
| Amgen INC. | $32.72 | 2025 | |
| Karyopharm Therapeutics INC. | $31.89 | 2021 | |
| Taiho Oncology, INC. | $31.83 | 2019 | |
| Gilead Sciences, INC. | $27.99 | 2019-2021 | |
| Kite Pharma, INC. | $26.29 | 2021 | |
| Dendreon Pharmaceuticals LLC | $25.26 | 2019 | |
| Rigel Pharmaceuticals, INC. | $23.95 | 2019 | |
| Array Biopharma INC | $23.06 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $21.80 | 2019 | |
| Emd Serono, INC. | $21.14 | 2019 | |
| Seagen INC. | $20.89 | 2020 | |
| Novartis Pharmaceuticals Corporation | $20.76 | 2019 | |
| Janssen Pharmaceuticals, INC | $19.07 | 2019 | |
| Ipsen Biopharmaceuticals, INC | $17.34 | 2020 | |
| Sanofi-Aventis U.S. LLC | $16.86 | 2019 | |
| Tolmar Pharmaceuticals, INC. | $13.95 | 2019 | |
| Eusa Pharma (US) LLC | $12.60 | 2020 | |
| Fortovia Therapeutics, INC. | $11.54 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edward Wagner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.